Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intrauterine system Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

SweetMama: Testing of a Novel Technology for Diabetes Education and Support to Pregnant Women

NCT03240874
View directory record Official record
Conditions
Diabetes Mellitus in Pregnancy
Interventions
SweetMama Focus Groups, SweetMama Individual Testing, SweetMama Feasibility Testing - Pilot Randomized Trial
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 21, 2026, 2:31 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Technology Development of Diagnostic Ultrasound System for Obstetric Imaging

NCT07590063
View directory record Official record
Conditions
Pregnancy
Interventions
Diagnostic Ultrasound System
Device
Lead sponsor
United Imaging Healthcare North America, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 21, 2026, 2:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods

NCT02456584
View directory record Official record
Conditions
Contraception
Interventions
DMPA 150, DMPA 300, DMPA 104
Drug
Lead sponsor
FHI 360
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 21, 2026, 2:31 PM EDT
Completed Not applicable Interventional

Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB)

NCT06634719
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Juveena Hydrogel System
Device
Lead sponsor
Rejoni Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Little Rock, Arkansas • West Orange, New Jersey • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 2:31 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Multicenter Analysis of Levonorgestrel-Intrauterine System (LNG-IUS) Use in the Postpartum Period

NCT01161095
View directory record Official record
Conditions
Contraception, Postpartum Period
Interventions
LNG-IUS
Device
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
Little Rock, Arkansas • Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 21, 2026, 2:31 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

NCT00995150
View directory record Official record
Conditions
Contraception
Interventions
LNG20, Mirena
Drug
Lead sponsor
Medicines360
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
1,910 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
25
States / cities
Phoenix, Arizona • Palo Alto, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 21, 2026, 2:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis

NCT04568980
View directory record Official record
Conditions
Cystic Fibrosis, Contraception
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
562 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 21, 2026, 2:31 PM EDT
Completed Phase 4 Interventional Results available

Postpartum Levonorgestrel-releasing Intrauterine System and Breastfeeding

NCT01555931
View directory record Official record
Conditions
Postpartum Contraception
Interventions
Levonorgestrel-releasing intrauterine system
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Oct 21, 2026, 2:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Does Skyla Insertion Timing Impact Bleeding?

NCT03074903
View directory record Official record
Conditions
Vaginal Bleeding
Interventions
Intrauterine system
Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Morristown, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 21, 2026, 2:31 PM EDT
Completed Phase 1 Interventional

Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer

NCT01485731
View directory record Official record
Conditions
Cervical Cancer
Interventions
Nelfinavir, Cisplatin, Pelvic External Beam Radiation Therapy, Brachytherapy, Pharmacokinetic Sampling, Cervical Biopsy, Pelvic Examination, Pap Smear, Audiogram, Proctoscopy, Cytoscopy, Renal Ultrasound, CT Scan, Whole Body PET/CT Scan
Drug · Radiation · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 21, 2026, 2:31 PM EDT
Completed Phase 4 Interventional Results available

Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users

NCT02362373
View directory record Official record
Conditions
Epilepsy, Contraception
Interventions
levonorgestrel IUS
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 21, 2026, 2:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Long-Acting Reversible Contraception

NCT01299116
View directory record Official record
Conditions
Contraception
Interventions
DMPA, oral contraceptives, Implanon®, ParaGard®, Mirena®
Drug
Lead sponsor
FHI 360
Other
Eligibility
18 Years to 29 Years · Female only
Enrollment
916 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 21, 2026, 2:31 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception

NCT02446821
View directory record Official record
Conditions
Contraception
Interventions
VeraCept
Drug
Lead sponsor
Sebela Women's Health Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
286 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
12
States / cities
Burbank, California • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 21, 2026, 2:31 PM EDT
Active, not recruiting No phase listed Observational

An Observational Study to Learn How Mirena and Other Progestogen Treatments Are Used for Endometrial Protection in Women 40+ With a Uterus in the United States Receiving Estrogen Therapy, and Their Respective Health Outcomes

NCT07795606
View directory record Official record
Conditions
Estrogen Therapy
Interventions
Estrogen therapy, Mirena levonorgestrel-releasing intrauterine system, Other progestogen therapy
Drug · Device
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
456,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Ann Arbor, Michigan • Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 2:31 PM EDT
Completed Not applicable Interventional Results available

Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression

NCT01613131
View directory record Official record
Conditions
Menopausal and Other Perimenopausal Disorders
Interventions
Mirena, Estradiol, Placebo Gel
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 52 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 21, 2026, 2:31 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Immediate Postpartum Insertion of Contraceptive Intrauterine Devices

NCT03657602
View directory record Official record
Conditions
Contraception
Interventions
Kyleena Intrauterine System, Mirena Intrauterine System
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 21, 2026, 2:31 PM EDT
Completed No phase listed Observational

Immediate Postpartum Nexplanon Placement in Opioid Dependent Women

NCT02657148
View directory record Official record
Conditions
Opiate Addiction, Pregnancy, Contraceptive Behavior, Sexual Behavior
Interventions
Nexplanon (etonogestrel contraceptive implant), Standard postpartum contraceptive care
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 21, 2026, 2:31 PM EDT
Completed Phase 4 Interventional Results available

A Pilot Study of Early Postpartum Intrauterine Contraception

NCT00997932
View directory record Official record
Conditions
Unplanned Pregnancy
Interventions
Levonorgestrel-Releasing Intrauterine Contraceptive System (LNG-IUS), 52 Mg, 5 Year Duration
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 21, 2026, 2:31 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35

NCT00161226
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Levonorgestrel intrauterine system
Device
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
35 Years to 50 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 21, 2026, 2:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Maintaining Intrauterine Devices (IUDs) in Teens (MINT): A Randomization Trial

NCT00653159
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel-releasing intrauterine device (LNG-IUS), Copper T380A intrauterine device (CuT380A)
Device
Lead sponsor
University of Chicago
Other
Eligibility
14 Years to 18 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 21, 2026, 2:31 PM EDT
Completed Not applicable Interventional Results available

Sonography Guided Transcervical Ablation of Uterine Fibroids

NCT02228174
View directory record Official record
Conditions
Menorrhagia
Interventions
Intrauterine Ultrasound-Guided Radiofreq. Ablation System
Device
Lead sponsor
Gynesonics
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
22
States / cities
Phoenix, Arizona • Denver, Colorado • Newark, Delaware + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 21, 2026, 2:31 PM EDT
Withdrawn Phase 3 Interventional

Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

NCT06904274
View directory record Official record
Conditions
Endometrial Hyperplasia
Interventions
BAY865028, Medroxyprogesterone acetate
Combination Product · Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
Phoenix, Arizona • Little Rock, Arkansas • West Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 21, 2026, 2:31 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Safety and Expulsion of Delayed Versus Immediate Postpartum Intrauterine Device Placement

NCT01598662
View directory record Official record
Conditions
Contraception
Interventions
Mirena (levonorgestrel-releasing intrauterine system)
Device
Lead sponsor
University of Louisville
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 21, 2026, 2:31 PM EDT
Active, not recruiting Phase 2 Interventional

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

NCT02397083
View directory record Official record
Conditions
Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions
Everolimus, Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System
Drug · Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
18
States / cities
Greeley, Colorado • Loveland, Colorado • Honolulu, Hawaii + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 2:31 PM EDT